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Objective: This study investigates the expression of Lewis y antigen, integrin αv, β3 in epithelial ovarian cancer
tissues. We further evaluate the relationship between their expression and chemotherapy resistance of ovarian
cancer and its possible clinical significance.
Methods: Tissues of 92 patients with ovarian cancer meeting the inclusion criteria with complete follow-up data
were enrolled and divided into chemotherapy resistant group and sensitive group. The expression and relationship
of Lewis y antigen and integrin αv, β3 are assessed in paraffin sections using immunohistochemistry and double-
labeling immunofluorescence method. Multivariate logistic regression analysis was used to investigate the
relationship between age, clinical stage, differentiation, histologic subtype, Lewis y antigen and integrin αv, β3
expression in ovarian cancer patients.
Results: The expression rates of Lewis y antigen and integrin αv in the resistant group, significantly higher than the
rates found in the sensitive group (p <0.05). Multivariate analysis showed that the expression of Lewis y antigen,
integrin αv and ovarian cancer’s clinical stage were independent, drug resistance-related risk factors. The expression
levels of Lewis y antigen and integrin αv, β3 were positively correlated with each other.
Conclusions: A close correlation between Lewis y antigen, integrin αv, β3 and ovarian cancer was observed. Lewis
y antigen can influence the biological behavior of a tumor cell as an important composition of integrin αv, β3 by
some signal pathway. And the expression of Lewis y antigen, integrin αv and ovarian cancer’s clinical stage are
both independent, drug resistance-related risk factors.
Keywords: Ovarian Cancer, Lewis y Antigen, Integrin αv, β3, Chemotherapeutic Drug ResistanceBackground
Ovarian cancer has the highest mortality rate of all can-
cers of the female reproductive system. Chemotherapy
resistance is an important factor influencing treatment
efficacy. In recent years, studies have shown that
through the interaction between surface adhesion mole-
cules and surrounding extracellular matrix, tumor cells
can promote proliferation, invasion, and metastasis, thus
improving their tolerance to chemotherapeutic drugs
[1]. Cell adhesion-mediated drug resistance (CAM-DR)
is a relatively new theory for the mechanism of drug* Correspondence: linbei88@hotmail.com
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reproduction in any medium, provided the orresistance in tumor cells [2-4]. Integrins comprise a large
family of cell adhesion molecules; they are transmem-
brane glycoproteins that play a key role in the inter-
action between cells and components of the interstitial
space. Integrin-mediated interactions between cells or
between cells and the extracellular matrix play an im-
portant role in tumor growth, invasion, metastasis, drug
resistance, and many other processes [5]. Many studies
have confirmed that carbohydrate antigens on the cell
surface are closely related to integrins. In our previous
work, we have found that as a part of the integrin αvβ3
structure, Lewis y antigen expression is related to the
degree of invasiveness of ovarian cancer [6]. Here we use
immunohistochemistry to further study the expression. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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from patients with chemotherapy resistant or sensitive
ovarian cancer and analyze how the expression of these
molecules correlates with chemotherapy resistance and
the resulting clinical significance.
Materials and methods
92 chosen paraffin samples are obtained from the ope-
rations done from 2006 to 2010 in the department of
Gynecology and Obstetrics of Sheng Jing Hospital Affili-
ated to China Medical University. After the cytoreductive
surgery and 6-8 periods of systematic chemotherapy, each
patient will receive a follow up observation for at least one
year. Among the 92 cases of primary epithelial ovarian
cancer studied, there are 58 cases of serous cystadeno-
carcinoma, 8 mucinous cystadenocarcinoma, 4 endo-
metrioid carcinoma, 7 clear cell carcinoma and 15 poorly
differentiated adenocarcinoma. According to histological
grade, there were 15 cases of high differentiated, 35 mod-
erate and 42 poor. The group includes 19 cases of stages I,
13 stages II, and 60 stages III (according to International
Federation of Gynecology and Obstetrics (FIGO) criteria).
All the cases are primary, the information and follow-up
data are complete; chemical treatment is not used in all
the patients before operations.
Drug resistance related clinical and pathological
parameters
Tissues obtained between 2006 and 2010 from 92 pa-
tients with ovarian cancer meeting the inclusion criteria
with complete follow-up data were enrolled. The clinical
and pathological parameters of ovarian cancer patients
include age, clinical stage, differentiation, histologic
subtype and chemotherapy scheme (PTX (paclitaxel) +
Carboplatin (TC)). According to the guideline of National
Comprehensive Cancer Network (NCCN) (recurrence
during the chemotherapy period or within 6 months after
the chemotherapy was define as drug resistance group;
after the chemotherapy recurrence between 6 to 12 months
was partial sensitive group and recurrence beyond
12 months after the chemotherapy or didn’t recurrenc was
sensitive group), the patients were divided into chemo-
therapy resistant group (34 cases) and sensitive group
(58 cases).
Main reagents
Mouse monoclonal anti-Lewis y antibody (clone A 70-
C/C8) was purchased from Abcam Company (UK).
Rabbit polyclonal anti-αv and anti-β3 antibodies were
purchased from Santa Cruz (USA). Goat monoclonal
anti-rabbit immunoglobulin G fluorescein isothiocyanate
(FITC) and goat monoclonal anti-mouse immunoglo-
bulin G tetramethyl rhodamine isothiocyanate (TRITC)
were purchased from Fujian Maixin Company (China).DAPI was purchased from Shenyang Baoxin Company
(China). Serum albumin (BSA) and DAB kit were
purchased from Zhongshan Biotechnology Company




try was performed. Tissues were fixed in 4% formalde-
hyde and embedded in paraffin, and 4 mm thick serial
sections were prepared at the same organizational part.
The working dilution of Lewis y antibody and integrin
αv, β3 antibody were 1:100 and 1:160, respectively. The
staining procedure was performed according to SP kit
manual. The group with PBS instead of primary anti-
body was used as a negative control. A colon cancer
sample served as positive control for Lewis y antigen,
and a breast cancer sample was a positive control for
integrin αv, β3.
Immunofluorescence
The sample slices of strong expression for immunohisto-
chemistry were selected to performed immunofluorescence
double labeling method. Primary antibody combinations
were anti-integrin αv with anti-Lewis y, or anti-integrin β3
with anti-Lewis y, with the PBS instead of primary antibody
as the negative control. The working dilution of rabbit
anti-human integrin αv, β3 and mouse anti-human Lewis y
antibody were all 1:160. The working dilution of goat anti-
rabbit IgM FITC and goat anti-mouse IgG TRITC were
1:100. The working dilution of nuclear dye DAPI was
1:100. The staining was performed according to the
instructions of immunofluorescence kit.
The determination of results
The presence of brown colored granules on the cell
membrane or in the cytoplasm was taken as a positive
signal, and was divided by color intensity into not
colored, light yellow, brown, tan and was recorded as 0,
1, 2, and 3, respectively. We choose five high-power
fields in series from each slice, then score them and take
the average percentage of chromatosis cells. A positive
cell rate of less than 5% was 0, 5 ~ 25% was 1, 26 ~ 50%
was 2, 51 ~ 75% was 3, more than 75% was 4. The final
score was determined by multiplying positive cell rate
and score values: 0 ~ 2 was considered negative (−), 3 ~
4 was (+), 5 ~ 8 was (++), 9 ~ 12 was (+++). The results
were read by two independent observers to control for
variability.
Microscopic red fluorescence indicated Lewis y anti-
gen labeled by TRITC, green fluorescence indicated
integrin αv, β3 labeled by FITC, while blue fluorescence
indicated DAPI-stained nucleus. Pictures of the three
individual fluorescence channels were superimposed
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indicated co-localization of Lewis y antigen and integrin
αv, β3.Statistical analysis
Statistical analyses were performed using the SPSS soft-
ware Version 11.5. Data expressed as mean ± SD was
applied for statistical analysis. The Student’s t test was
applied to compare data between the two groups, and
analysis of variance was applied to compare data among
multiple groups.
The Chi-square (χ2) test was applied to analyze the
expression of Lewis y antigen, integrin αv, β3 and clini-
copathological parameters. The Spearman correlation
analysis method was applied to calculate the coefficient R
of indexes and to analyze its correlation, A P value <0.05
was considered statistically significant.Figure 1 Expression of Lewis y antigen in resistant group (Fig.A: stag
sensitive group (Fig.B: stage IIIc, poorly differentiated serous cystade
(Fig.C: stage IIIc, moderate differentiated serous cystadenocarcinoma
serous cystadenocarcinoma)(*200); Expression of Lewis y antigen in r
endometrioid carcinoma)and sensitive group (Fig.F: stage IIIc, moderResults
Expression of Lewis y antigen, integrin αv and β3 in
different groups
Lewis y antigen was expressed in the cytoplasm and cell
membrane, mainly on membrane and rarely in the
nucleus. The expression rates of Lewis y antigen in the
resistant group were 91.67%, significantly higher than
60.34% in the sensitive group (p <0.05), as shown in
Figure 1 and Table 1.
Similar to Lewis y, the expression of integrin αv and
β3 were mainly on membrane. The integrin αv positive
expression rate was 85.29% in the resistant group,
significantly higher than that of the sensitive group
(51.72%) (P < 0.05). The expression rate of integrin β3 in
the resistant group was 88.24%, higher than 65.52% in
the sensitive group, but there were no significant
difference between these two groups (p > 0.05), Figure 1
and Table 2.e IIIc, moderate differentiated serous cystadenocarcinoma) and
nocarcinoma)(*200); Expression of integrin av in resistant group
) and sensitive group (Fig.D: stage IIIc, moderate differentiated
esistant group (Fig.E: stage IIIc, moderate differentiated
ate differentiated endometrioid carcinoma)(*200).
Table 1 Expression of Lewis y antigen in different groups
Groups Cases Lewis y antigen Positive
cases
Positive
rate (%)- + ++ +++
Resistant group 34 3 4 19 8 31 91.18
Sensitive group 58 23 16 19 0 36 60.34
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The clinical and pathological parameters of ovarian
cancer patients include age, clinical stage, differentiation,
histologic subtype, only ovarian cancer’s clinical stage
were independent, drug resistance-related risk factors
(P = 0.01), the difference between the rest factors was
not significant (p > 0.05), as shown in Table 3.
Drug resistance-related risk factors multivariate logistic
regression analysis
Multivariate logistic regression analysis was used to
investigate the relationship between age, clinical stage,
differentiation, histologic subtype, and Lewis y antigen
and integrin αvβ3 expression in ovarian cancer patients
with ovarian cancer chemotherapy resistance. The result
showed that both the expression of Lewis y antigen and
integrin αv and ovarian cancer’s clinical stage were inde-
pendent, drug resistance-related risk factors, as shown in
Table 4.
In addition, immunofluorescence double-labeling re-
vealed that in ovarian cancer Lewis y antigen (red fluores-
cence) was localized in the cell membrane and cytoplasm.
Integrin αv and β3 (green fluorescence) were mainly
localized in the cell membrane, with a small amount of
coloring in the cytoplasm. The 4,6-diamino-2-phenyl
indole (DAPI) (blue fluorescence) was used to visualize
the nucleus. In three-channel synthesized images, the
yellow fluorescence emerges from the area emitting both
red and green fluorescence, indicating co-localization of
Lewis y antigen and integrin αv, β3, as shown in Figure 2.
Correlation analysis between expression of Lewis y
antigen and integrin αv, β3 in ovarian cancer
A similar trend was seen in the expression of Lewis y
antigen, integrin αv, β3 in 92 patients with ovarian
cancer, according to the results of immunohistochemis-
try. Both Lewis y antigen and integrin αvβ3 showed high
expression in the ovarian cancer resistant group andTable 2 Expression of integrin αv and β3 in different groups
Groups Cases Integrin αv
- + ++ +++ Positive cases Positiv
Resistant group 34 5 8 11 10 29 85.29
Sensitive group 58 28 16 6 8 30 51.72their expression levels were positively correlated with
each other (Tables 5, 6 Figure 1).
In order to investigate the correlation between these
two antigens, we performed Spearman correlation
analysis for each set of data, which demonstrated a high
degree of positive correlation between Lewis y and integ-
rin αv (correlation coefficients were 0.235 , P < 0.05), β3
(correlation coefficients were 0. 333 , P < 0.01 ) subunits.
Discussion
Chemotherapy resistance has been proven to be a very
difficult issue in the treatment of ovarian cancer. The
mechanisms of resistance and appropriate countermea-
sures targeting these mechanisms have become hotspots
in ovarian cancer research. Previous studies of the me-
chanism of resistance in ovarian cancer mainly focused
on drug concentration in tumor cells, DNA damage
repair mechanisms, glutathione-dependent detoxification
enzyme system activity, and other aspects. In recent
years, a number of studies on malignant tumor drug
resistance have found that tumor drug resistance is
related to changes in adhesion molecule composition,
the adhesion abilities of tumor cells, and the resultant
cytoskeletal rearrangements and signal transduction path-
way activation. Therefore, a new mechanism of tumor
drug resistance—cell adhesion mediated drug resistance
(CAM-DR) has been proposed [2-4].
The adhesion of tumor cells to the surrounding envi-
ronment can improve cell survival and anti-apoptotic
ability. Integrins are important cell surface adhesion
molecules as they are receptors for many extracellular
matrix components. Integrin receptors can regulate cell
growth, differentiation, and metastasis through trans-
membrane signal transduction. Tumor cell growth and
metastasis are both closely related to drug resistance.
Metastasized tumor cells are more likely to be drug
resistant and resistant tumor cells have a stronger ability
to metastasize or invade. The relationship between
integrins and drug resistance is gradually gaining recog-
nition, but the research is still in early stages [7-9].
Damiano et al [10] found that the expression of integrin
α4β1 in the drug-resistant strain, RPMI8226/S, of hu-
man multiple myeloma cell strain RPMI8226 was signifi-
cantly higher than that in sensitive strains; furthermore,
extracellular matrix-coated cells significantly increased
the cells’ tolerance of the chemotherapeutic drugsIntegrinβ3
e rate(%) - + ++ +++ Positive cases Positive rate(%)
4 10 10 10 30 88.24
20 21 15 2 38 65.52














I 19 1 2.94 18 31.03 0.01
II 13 3 8.82 10 17.24
III 60 30 88.24 30 51.72
IV 0 0 0 0 0
Differentiation
High 15 5 14.71 10 17.24 0.298
Moderate 35 12 35.29 23 39.66




58 24 70.59 34 58.62 0.872
Mucinous
cystadenocarcinoma
8 4 11.76 4 6.90
Endometrioid carcinoma 4 1 2.94 3 5.17
Clear cell carcinoma 7 1 2.94 6 10.34
Poorly differentiated
adenocarcinoma
15 4 11.76 11 18.87
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apoptosis. Similar findings have been observed for
leukemia, glioma, breast cancer and small cell lung can-
cer. In preliminary studies, we have also demonstrated
that the ovarian cancer cell line, RMG-I-h, with high ex-
pression of the integrins α5β1 and αvβ3, can increase
drug resistance to 5-FU, carboplatin, and paclitaxel
[11,12].
Integrin glycosylation status has been shown to affect
the strength of integrin-ligand binding and the forma-
tion of the glycosidic bond catalyzed by glycosyltransfer-
ase affecting the glycosylation status of integrins. The
fucose sugar has been shown to be a component of
integrin molecules. Furthermore, core fucosylation isTable 4 Drug resistance-related risk factors multivariate
logistic regression analysis
Factors B Sx P OR 95% CI
Lewis y antigen −2.249 0.605 0.000 0.106 0.032 0.345
Integrin αv −0.968 0.415 0.020 0.380 0.168 0.857
Clinical stage −1.304 0.575 0.023 0.271 0.088 0.838
B: model parameter.
Sx: standard error of mean.
P: P value.
OR: odds ratio.essential for integrin-mediated cell migration and signal
transduction and plays a key role in the interaction
between cells and extracellular matrix, thus affecting
tumor metastasis. E. W. Easton et al [13] purified α5β1
integrin from human placenta and α3β1 integrin from
the uterine epithelial cell line, HCV29, and demon-
strated that both integrins were more than 50%
fucosylated. Zhao et al [14] found that knockout of the
α1,6-fucose transferase gene (FT8) could prevent in-
tegrin α3β1-mediated cell migration and cell growth
signals, suggesting that core fucosylation is required for
the functions of integrin α3β1. Lewis y antigen is an
oligosaccharide containing two fucose molecules and
falls into the A, B, H, and Lewis blood type families. The
role of Lewis y antigen as a cancer-associated antigen in
tumorigenesis and development gradually arouses more
concern. We have previously demonstrated that the
Lewis y antigen is a part of the α5β1 and αvβ3 structures
and high expression of Lewis y antigen and integrins
α5β1 and αvβ3 can enhance the proliferative and adhe-
sive abilities of cells [6,15]. Furthermore, we have shown
We have also previously shown that cell lines and
clinical ovarian cancer specimens exhibiting increased
expression of Lewis y antigens in integrins α5β1 and
αvβ3 are more likely to exhibit a malignant phenotype
[6,15,16]. Our studies have also shown that Lewis y anti-
gen can increase the ability of α5β1 and αvβ3 to bind
their ligands, fibronectin (FN) and vitronectin (VN),
thereby increasing the cells’ resistance to platinum drugs
by enhancing cellular adhesion [6,15,17].
On the basis of this body of work, we retrospectively
analyzed the expression of Lewis y antigen and integrin
αvβ3 in the tissue specimens of patients resistant to
platinum drugs and investigated their relationship with
drug resistance. We found the rates of expression of
Lewis y antigen and αv integrins in the resistant group
were significantly higher than those in the sensitive
group (P < 0.05); however, the expression rate of integrin
β3 in the two groups was not significantly different.
Multivariate analysis showed that the expression of
Lewis y-antigen and integrin αv and the clinical stage of
ovarian cancer were both independent drug resistance-
related risk factors, suggesting that the detection of
Lewis y antigen and integrin αvβ3 could play an import-
ant role in the prediction of ovarian cancer patients’
drug resistance, prognosis, and outcome. Correlation
analysis showed that Lewis y antigen and integrin sub-
units αv and β3 in ovarian cancer tissues were highly
expressed in ovarian cancer cells and their expression
levels were positively correlated with each other. Dual-
color immunofluorescence labeling indicated that Lewis
y antigen and integrin αvβ3 were co-localized in ovarian
cancer tissues, further confirming their correlation
of expression.
Figure 2 Integrin αv, β3 and Lewis y colocalize in ovarian malignant tumor. Integrin αv and β3 (A and E); Lewis y (B and F); Nucleus
(C and G); Merged image (D and H)( *400).
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can increase the activity of protein tyrosine kinase
(PTK), resulting in more tumor cells in G1 phase and
phosphoinositide 3 kinase activation [18]. Lewis y anti-
gen is not only a part of the integrin α5β1 and αvβ3
structures, but is also a part of the structure of other
adhesion molecules such as CD44 [19]. Therefore,
increased expression of Lewis y antigen can improve the
adhesion of cells to the matrix and promote cell adhe-
sion and metastasis through corresponding signal trans-
duction pathways. These actions can then enhance cell
behaviors that promote malignancy which provides a
theoretical basis for altering Lewis y antigen expression
and/or downstream signaling modification in the treat-
ment of ovarian cancer. Although the mechanism by
which adhesion molecule fucosylation affects drug resis-
tance is not yet clear, it is currently believed that
integrin-mediated tumor cell resistance is related to the
following factors: (1) regulating apoptosis (Bax/BclX); (2)
changing the drug targets (of Topo II); (3) inhibitingTable 5 Correlation between expression of Lewis y




Positive cases Negative cases
Positive cases 46 20 66
Negative cases 13 13 26
Total 59 33 92DNA injury, and enhancing DNA repair; (4) regulating
P27 protein, etc. Our studies have shown that Lewis y-
antigen is involved in the aforementioned process, and
increases tumor cell drug resistance [15,17]. As a part of
the integrin α5β1 and αvβ3 structures, Lewis y antigen
can promote the adhesion of integrins to extracellular
matrix in order to strengthen focal adhesion kinase (FAK)
phosphorylation; increased expression of Lewis y antigen
would activate FAK signal transduction pathways, increase
cell adhesion, and increase drug resistance by regulating
Topo-T, Topo-Iiβ, Bcl-2, and Bcl-XL.
These results suggest that the immunohistochemical
detection of Lewis y antigen and integrin αvβ3 in
ovarian cancer tissues can be used as important indi-
cators for determining appropriate clinical chemothe-
rapy, prognosis, and outcome. In-depth understanding
of signaling transduction pathways for integrin-
mediated chemotherapy resistance will provide a basis
for increasing chemosensitivity and developing new
chemotherapies.Table 6 Correlation between expression of Lewis y




Positive cases Negative cases
Positive cases 52 14 66
Negative cases 16 10 26
Total 68 24 92
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